Pre-exposure prophylaxis for HIV infection may be effective in older candidates, but proceed with caution

摘要

The effectiveness and safety of tenofovir (TDF)-based therapy, which is the standard for pre-exposure prophylaxis (PrEP) for HIV infection, have not been specifically evaluated in older individuals. Major concerns relate to the older population being predisposed to kidney- and/or bone-related adverse events if they receive TDF-based PrEP. However, TDF-based PrEP may be a manageable treatment option in older candidates if careful screening, regular monitoring and appropriate sexual health education are also incorporated into the prevention plan.